RayKnowChina Research Map
Shortlist

Beijing

Beijing Jishuitan Hospital

北京积水潭医院

Listed for 7 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Beijing Jishuitan Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Chordoma脊索瘤0 papers led
  2. Osteosarcoma骨肉瘤21 papers led
  3. Ewing sarcoma尤文肉瘤1 paper led
  4. Multiple myeloma多发性骨髓瘤6 papers led
  5. Takayasu arteritis大动脉炎0 papers led
  6. Amyotrophic lateral sclerosis肌萎缩侧索硬化症0 papers led
  7. Osteogenesis imperfecta成骨不全症1 paper led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Gastrointestinal stromal tumour, Neuroblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

9 hospitals in Beijing for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Earlier papers (2016–2020)6
  1. [Interpretation of 2020 NCCN Clinical Practice Guidelines in Oncology-Bone Cancer].2020Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. The clinical outcome of recurrent sacral chordoma with further surgical treatment.2018Medicine
  3. [Dedifferentiated chordoma of sacrococcygeal region: a clinicopathologic analysis and review of literature].2018Zhonghua bing li xue za zhi = Chinese journal of pathology
  4. Recurrence and survival factors analysis of 171 cases of sacral chordoma in a single institute.2017European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  5. [Updates and interpretations of 2017 NCCN guidelines for bone cancer].2017Zhonghua wai ke za zhi [Chinese journal of surgery]
  6. Computer Navigation-aided Resection of Sacral Chordomas.2016Chinese medical journal

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 21 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
21
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 6620212022: 3320222023: 5520232024: 3320242025: 442025

37 hospitals in Beijing for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicine

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led21
  1. Is Proximal Tibial Hemiarthroplasty Reconstruction Effective in Minimizing Limb Length Discrepancy Among Skeletally Immature Patients With Primary Bone Sarcomas?2025Clinical orthopaedics and related research
  2. The clinical outcomes of joint-preserving endoprosthesis reconstruction for primary sarcomas about the knee.2025Journal of orthopaedic surgery and research
  3. Soft tissue reconstruction of tumor-related proximal tibial hemiarthroplasty using synthetic mesh combined with a medial gastrocnemius flap.2025Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology
  4. Synergistic Defect-Driven Chemocatalysis and Ultrasound-Activated Piezocatalysis by Two-Dimensional SnSe Nanosheets.2025Nano letters
  5. Survival and functional outcomes after hemiarthroplasty in children with proximal tibial osteosarcoma.2024Journal of orthopaedic surgery and research
  6. The correlation between clinical outcomes and genomic analysis with high risk factors for the progression of osteosarcoma.2024Molecular oncology
  7. An innovative staged prosthetic lengthening reconstruction strategy for osteosarcoma-related leg discrepancy.2024Scientific reports
  8. Caulis Spatholobi extracts inhibit osteosarcoma growth and metastasis through suppression of CXCR4/PI3K/AKT signaling.2023Journal of orthopaedic surgery and research
  9. Metastasis-Related Signature for Clinically Predicting Prognosis and Tumor Immune Microenvironment of Osteosarcoma Patients.2023Molecular biotechnology
  10. Carboxypeptidase E is a prognostic biomarker co-expressed with osteoblastic genes in osteosarcoma.2023PeerJ
  11. Genomic and transcriptomic characterization of pre-operative chemotherapy response in patients with osteosarcoma.2023Scientific reports
  12. Accuracy of bony resection under computer-assisted navigation for bone sarcomas around the knee.2023World journal of surgical oncology
  13. Preparation of polycation with hydroxyls for enhanced delivery of miRNA in osteosarcoma therapy.2022Biomaterials science
  14. Detection and Quantification of Circulating Tumor Cells in Salvaged Blood in Surgical Osteosarcoma Patients: A Pilot Study from a Tertiary Medical Center.2022Biomedical and environmental sciences : BES
  15. The expression of hydrogen sulfide-producing enzymes in primary and lung metastatic osteosarcoma.2022Histology and histopathology
  16. Whole-exome sequencing in osteosarcoma with distinct prognosis reveals disparate genetic heterogeneity.2021Cancer genetics
  17. Computer navigation-aided joint-preserving resection and custom-made endoprosthesis reconstruction for bone sarcomas: long-term outcomes.2021Chinese medical journal
  18. Detection of BCOR gene rearrangement in Ewing-like sarcoma: an important diagnostic tool.2021Diagnostic pathology
  19. Centralization of ulna with wrist fusion for failure of reconstructed distal radius by allograft bone or prosthesis: A case report and literature review.2021Medicine
  20. Mesh patch and anchors can improve clinical results of prosthetic replacement after resection of primary proximal humerus malignant tumor.2021Scientific reports
  21. Chemotherapy-induced amenorrhea and its effects on fertility in long-term female survivors of classic osteosarcoma.2021Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Chinese-language papers (not in the count)6
  1. [Advances in the pathology of bone lesions in China over the past ten years: retrospect and prospect].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Malignant transformation of polyostotic fibrous dysplasia in long bone: a clinicopathological analysis of four cases].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
  3. [Detection of EWSR1 gene rearrangement by fluorescence in situ hybridization in bone and soft tissue tumors: clinical application evaluation and atypical signal analysis].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
  4. [Detection of MDM2 gene amplification by fluorescence in situ hybridization and its diagnostic value in low-grade osteosarcoma].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
  5. [Radiation-associated sarcomas of bone and soft tissue: a clinicopathological analysis of 46 cases].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  6. [Mutation characteristics of osteosarcoma: a single center study of 64 cases using next-generation sequencing].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
Earlier papers (2016–2020)10
  1. Anti-osteosarcoma effect of hydroxyapatite nanoparticles both in vitro and in vivo by downregulating the FAK/PI3K/Akt signaling pathway.2020Biomaterials science
  2. Bone defect reconstruction with autologous bone inactivated with liquid nitrogen after resection of primary limb malignant tumors: An observational study.2020Medicine
  3. [Effectiveness and safety of polyethylene glycol liposome doxorubicin in the treatment of osteosarcoma].2020Zhonghua zhong liu za zhi [Chinese journal of oncology]
  4. Comparative Analysis of Early Follow-up of Biologic Fixation and Cemented Stem Fixation for Femoral Tumor Prosthesis.2019Orthopaedic surgery
  5. [Application of proximal tibial hemiprosthesis replacement and second-stage revision for proximal tibial osteosarcoma in three children].2019Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  6. [Synchronous multicentric osteosarcoma: treatment and prognostic factor analysis].2019Zhonghua yi xue za zhi
  7. Transition from Tumor Tissue to Bone Marrow in Patients with Appendicular Osteosarcoma after Neoadjuvant Chemotherapy.2017Chinese medical journal
  8. [Updates and interpretations of 2017 NCCN guidelines for bone cancer].2017Zhonghua wai ke za zhi [Chinese journal of surgery]
  9. Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients.2016Chinese medical journal
  10. Is There a Reliable Method to Predict the Limb Length Discrepancy after Chemotherapy and Limb Salvage Surgery in Children with Osteosarcoma?2016Chinese medical journal
All its trials on ClinicalTrials.gov, any status1
  1. Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment FailureCompletedNCT06935409Study sitePhase 3Start 2025-04

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

16 hospitals in Beijing for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led1
  1. Detection of BCOR gene rearrangement in Ewing-like sarcoma: an important diagnostic tool.2021Diagnostic pathology
Chinese-language papers (not in the count)1
  1. [Detection of EWSR1 gene rearrangement by fluorescence in situ hybridization in bone and soft tissue tumors: clinical application evaluation and atypical signal analysis].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
Earlier papers (2016–2020)1
  1. [Updates and interpretations of 2017 NCCN guidelines for bone cancer].2017Zhonghua wai ke za zhi [Chinese journal of surgery]

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 6 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.4%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 2220242025: 002025

14 hospitals in Beijing for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2024-06
    Registry
    NCT06574568

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Jinan, Taiyuan, Zhengzhou

  2. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskDrug combinationsKidney & bone complications

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led6
  1. R2-ISS staging combined with circulating plasma cells improves risk stratification for newly diagnosed multiple myeloma: a single-center real-world study.2024Annals of hematologyFree full text
  2. Validation of the IMPEDE VTE score for prediction of venous thromboembolism in Chinese patients with multiple myeloma: A single-center retrospective cohort study.2024Thrombosis research
  3. Risk-benefit ratio of percutaneous kyphoplasty and percutaneous vertebroplasty in patients with newly diagnosed multiple myeloma with vertebral fracture: a single-center retrospective study.2023Annals of hematologyFree full text
  4. BDNF/TrkB confers bortezomib resistance in multiple myeloma by inducing BRINP3.2023Biochimica et biophysica acta. General subjects
  5. Front-line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a real-world setting: A multicenter retrospective study in China.2023Cancer medicineFree full text
  6. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.2022Journal of clinical laboratory analysisFree full text
Chinese-language papers (not in the count)1
  1. [Comparison of the predictive value of Padua and the IMPEDE assessment scores for venous thromboembolism in patients with newly diagnosed multiple myeloma: A single institution experience].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status5
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. A Study of YKST02 in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06574568Study sitePhase 1Start 2024-06
  3. A Study of NINLARO® in Chinese Adults With Multiple MyelomaActive, not recruitingNCT05013190Study siteStart 2021-10
  4. A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory MyelomaTerminatedNCT04735575Study sitePhase 1/Phase 2Start 2021-05
  5. A Study of Ninlaro in Real World Clinical Practice in ChinaCompletedNCT04328662Study siteStart 2020-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

24 hospitals in Beijing for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Earlier papers (2016–2020)1
  1. Clinical Characteristics of Heart Involvement in Chinese Patients with Takayasu Arteritis.2017The Journal of rheumatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led no English-language PubMed papers on amyotrophic lateral sclerosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

15 hospitals in Beijing for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

5 hospitals in Beijing for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

北京积水潭医院

Beijing Jishuitan Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
JST Hospital; 北京市创伤骨科研究所

Suggest a correctionDownload the data